Cytek Biosciences, Inc. (CTKB) stock intrinsic value fair value estimate & owner earnings analysis

Cytek Biosciences sells full-spectrum flow cytometry systems used by pharmaceutical companies, contract research organizations, and academic and government labs to measure many markers on individual cells at once. Its main instruments are the Cytek Aurora, Northern Lights, Cytek Aurora Evo and Aurora CS systems; in February 2023 it bought Luminex's flow cytometry and imaging business (Amnis ImageStream, Guava and Muse products) for about $44.9 million. It also sells reagents and service contracts on its installed base. Instruments are made at the company's own plant in Wuxi, China (clinical-use instruments are made only there) and at a second plant in Singapore that began operating in March 2025. What the business earns. Revenue has stalled: $193.0 million in 2023, $200.5 million in 2024 and $201.5 million in 2025, with the first half of 2026 up about 6% to $92.3 million. We measure the cash the owners actually keep: operating cash flow with working-capital swings removed, less stock-based compensation (about $24.6 million in 2025, which we treat as a real cost) and less the capital spending needed to keep the business running. On that basis Cytek was roughly break-even in 2021 and 2022 and has lost money every year since the Luminex deal: about -$13.5 million in 2023, -$16.8 million in 2024 and -$33.8 million in 2025 (-$0.10, -$0.13 and -$0.26 per share). The 2025 reported net loss of $66.5 million was larger mainly because of a $33.6 million non-cash deferred tax charge, which does not affect cash and is not counted against owners here. 2025 also saw gross margin fall from 55% to 52%, which the company attributes to higher tariff costs and higher overhead from transitioning a manufacturing facility overseas, and the company says cuts to NIH indirect-cost reimbursement have hurt sales to academic and government customers. We add back intangible amortization (about $3.7 million a year from acquisitions) as a sunk cost, but we keep lease payments and the royalty and settlement payments owed to BD under their October 2020 settlement as real costs. Interest on the investment portfolio is left out of earnings because the cash itself is counted at full value below. Starting point. We use the median of the three years since the Luminex acquisition, which is the 2024 level of about -$16.8 million a year (-$0.13 per share). Earlier years describe a smaller business before the acquisition. 2025 was about $17 million worse than 2024, but we start the base case at the 2024 level rather than the 2025 level because the first half of 2026 improved: owner earnings were about -$10.2 million versus -$17.7 million in the first half of 2025, although $3.1 million of that improvement was a net tax refund. No revenue growth, margin recovery or cost savings is credited in any case: none is contracted or the product of a long, repeatable record. Balance sheet. At June 30, 2026 Cytek held $73.8 million of cash and $188.2 million of marketable securities ($262.0 million in total) against about $9.4 million of loans. We set aside $25 million as working cash, leaving $237.0 million of surplus cash, or about $227.6 million after repaying the loans (roughly $1.75 per share on about 130.0 million shares). The company spent $80.8 million buying back stock from 2023 through 2025. The remaining settlement liability to BD (about $8.7 million) is paid out of operating cash flow and is already charged in owner earnings, so it is not subtracted again. Base case ($0.80 per share). Losses continue at the 2024 rate of about $16.8 million a year for ten years, then stop. The business is worth about -$123.6 million today at a 6% discount rate; the company owes about $9.4 million and holds $237.0 million of surplus cash, so shareholders are left with roughly $103.9 million. Nothing after year ten is credited because we cannot point to evidence of a lasting profit. Bear case ($0.25 per share). The 2025 problems (higher tariff costs, weaker academic demand after the NIH changes, and overhead from transitioning manufacturing overseas) persist for five years at about $33.8 million a year before easing back to the $16.8 million rate for five more. The business is worth about -$195.3 million; after the same $9.4 million of debt and $237.0 million of surplus cash, shareholders keep about $32.3 million. In this case most of the cash pile is used up within ten years. Bull case ($1.64 per share). The first-half 2026 improvement continues: the loss narrows to about $10 million in 2026 and $5 million in 2027, then the business runs at the break-even level it actually achieved in 2021 and 2022. The business is worth about -$13.9 million; after the $9.4 million of debt and $237.0 million of surplus cash, shareholders are left with about $213.7 million, close to the surplus cash itself. We do not credit a return to real profitability because the business has not produced meaningfully positive owner earnings in any year since its 2021 IPO. What would make this wrong. The value here rests almost entirely on the cash, so the key question is whether management keeps spending it on losses. If Cytek can show two or three years of positive cash earnings after stock compensation, for example by lifting service and reagent revenue from its installed base or recovering gross margin as the Singapore plant ramps, the shares would be worth considerably more than these cases suggest. If the losses deepen again or the cash goes to another acquisition that does not pay, the value falls toward the bear case.